-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Endovascular treatment of acute ischemic stroke has shown great efficacy, with a reperfusion rate of over 80%.
Stroke, vascular biggest challenge in acute ischemic stroke study now is not just reperfusion, also includes ischemia-reperfusion injury, including the blood-brain barrier damage, cerebral edema and cerebral parenchymal hemorrhage.
Between June 21, 2017 and September 27, 2019, the four participating stroke centers recruited a total of 324 patients: 162 patients were randomly assigned to the intensive target group, and 162 patients were assigned to the standard target group.
Within 24-36 hours after reperfusion, 65 (42%) of the 154 patients in the enhanced target group and 68 (43%) of the 157 patients in the standard target group were observed on brain CT.
Compared with the standard treatment systolic blood pressure goal, the results in this article have no evidence that the intensive strategy of reducing the systolic blood pressure to 100-129mmHg within 24-36 hours in patients with acute ischemic stroke after successful endovascular treatment is effective in reducing imaging intraparenchymal bleeding Any impact.
There is no evidence that the intensive strategy of reducing the systolic blood pressure to 100-129mmHg in patients with acute ischemic stroke within 24-36 hours after successful endovascular treatment has any effect on reducing imaging intraparenchymal bleeding.
Mazighi, MikaelMazighi, Mikael et al.
Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.
The Lancet Neurology, Volume 20, Issue 4 , 265-274 Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial.
Leave a message here
